Analyst Anthony Vendetti of Maxim Group maintained a Buy rating on SeaStar Medical Holding (ICU – Research Report), with a price target of $7.00.
Anthony Vendetti has given his Buy rating due to a combination of factors including SeaStar Medical Holding’s recent clinical, regulatory, and commercial milestones. The company achieved FDA approval and launched its QUELIMMUNE device for pediatric patients with acute kidney injury (AKI) due to sepsis, which has been well-received by pediatric hospitals, showing a strong conversion rate. This success in the pediatric market is expected to drive revenue growth throughout 2025.
Additionally, SeaStar is making significant progress in its NEUTRALIZE-AKI clinical trial for adult patients, with patient enrollment on track and expectations to finalize enrollment by the end of 2025. The adult AKI market presents a substantial opportunity, being significantly larger than the pediatric segment. The company’s innovative Selective Cytopheretic Device (SCD) technology, combined with its strategic advancements, supports a positive outlook. The valuation, based on a 10-year discounted cash flow analysis, indicates a 12-month price target of $7.00, reflecting the promising market potential and technological innovation.